Home » Stocks » TIL

Instil Bio, Inc. (TIL)

Stock Price: $17.81 USD 0.41 (2.36%)
Updated Jun 17, 2021 1:30 PM EDT - Market open
Market Cap 2.24B
Revenue (ttm) 94,000
Net Income (ttm) n/a
Shares Out 34.98M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 17
Last Price $17.81
Previous Close $17.40
Change ($) 0.41
Change (%) 2.36%
Day's Open 17.48
Day's Range 17.42 - 18.50
Day's Volume 173,552
52-Week Range 14.42 - 29.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...

2 weeks ago - GlobeNewsWire

IPO in March 2021 raising $368M in gross proceeds

1 month ago - GlobeNewsWire

The clinical-stage cell therapy company reported impressive response rates for its candidate treatment against metastatic melanoma.

1 month ago - The Motley Fool

DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma...

1 month ago - GlobeNewsWire

67% overall response rate and 19% complete response rate in 21 patients

2 months ago - GlobeNewsWire

DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...

2 months ago - GlobeNewsWire

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

Other stocks mentioned: AFCG, CNTB, FNCH, GANX, JWEL, NAPA, OLO ...
2 months ago - Benzinga

DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...

2 months ago - GlobeNewsWire

Instil Bio, an early stage biotech developing cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

3 months ago - NASDAQ

Instil Bio, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About TIL

Instil Bio is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. Using our optimized and scalable manufacturing process, we are advancing our lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. We plan to submit an investigational new drug application, or IND, to the FDA, and, if authorized to proceed, initiate a Phase 2 trial in the second half of 2021. We plan to ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 19, 2021
CEO
Bronson Crouch
Employees
242
Stock Exchange
NASDAQ
Ticker Symbol
TIL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Instil Bio is 28.67, which is an increase of 60.98% from the latest price.

Price Target
$28.67
(60.98% upside)